Merck & Co. Statistics
Total Valuation
Merck & Co. has a market cap or net worth of $321.57 billion. The enterprise value is $364.99 billion.
| Market Cap | 321.57B |
| Enterprise Value | 364.99B |
Important Dates
The next confirmed earnings date is Tuesday, August 4, 2026, before market open.
| Earnings Date | Aug 4, 2026 |
| Ex-Dividend Date | Sep 15, 2026 |
Share Statistics
Merck & Co. has 2.47 billion shares outstanding. The number of shares has decreased by -1.79% in one year.
| Current Share Class | 2.47B |
| Shares Outstanding | 2.47B |
| Shares Change (YoY) | -1.79% |
| Shares Change (QoQ) | -0.64% |
| Owned by Insiders (%) | 0.05% |
| Owned by Institutions (%) | 80.81% |
| Float | 2.47B |
Valuation Ratios
The trailing PE ratio is 36.41 and the forward PE ratio is 21.09. Merck & Co.'s PEG ratio is 3.28.
| PE Ratio | 36.41 |
| Forward PE | 21.09 |
| PS Ratio | 4.89 |
| Forward PS | 4.79 |
| PB Ratio | 7.01 |
| P/TBV Ratio | n/a |
| P/FCF Ratio | 22.78 |
| P/OCF Ratio | 17.97 |
| PEG Ratio | 3.28 |
Enterprise Valuation
The stock's EV/EBITDA ratio is 20.05, with an EV/FCF ratio of 25.86.
| EV / Earnings | 40.85 |
| EV / Sales | 5.55 |
| EV / EBITDA | 20.05 |
| EV / EBIT | 30.53 |
| EV / FCF | 25.86 |
Financial Position
The company has a current ratio of 1.30, with a Debt / Equity ratio of 1.07.
| Current Ratio | 1.30 |
| Quick Ratio | 0.70 |
| Debt / Equity | 1.07 |
| Debt / EBITDA | 2.70 |
| Debt / FCF | 3.48 |
| Interest Coverage | 7.85 |
Financial Efficiency
Return on equity (ROE) is 18.94% and return on invested capital (ROIC) is 21.18%.
| Return on Equity (ROE) | 18.94% |
| Return on Assets (ROA) | 12.58% |
| Return on Invested Capital (ROIC) | 21.18% |
| Return on Capital Employed (ROCE) | 11.75% |
| Weighted Average Cost of Capital (WACC) | 4.98% |
| Revenue Per Employee | $876,907 |
| Profits Per Employee | $119,133 |
| Employee Count | 75,000 |
| Asset Turnover | 0.54 |
| Inventory Turnover | 2.42 |
Taxes
In the past 12 months, Merck & Co. has paid $2.70 billion in taxes.
| Income Tax | 2.70B |
| Effective Tax Rate | 23.17% |
Stock Price Statistics
The stock price has increased by +59.27% in the last 52 weeks. The beta is 0.20, so Merck & Co.'s price volatility has been lower than the market average.
| Beta (5Y) | 0.20 |
| 52-Week Price Change | +59.27% |
| 50-Day Moving Average | 122.86 |
| 200-Day Moving Average | 111.59 |
| Relative Strength Index (RSI) | 58.58 |
| Average Volume (20 Days) | 8,076,290 |
Short Selling Information
The latest short interest is 29.36 million, so 1.19% of the outstanding shares have been sold short.
| Short Interest | 29.36M |
| Short Previous Month | 30.27M |
| Short % of Shares Out | 1.19% |
| Short % of Float | 1.19% |
| Short Ratio (days to cover) | 2.59 |
Income Statement
In the last 12 months, Merck & Co. had revenue of $65.77 billion and earned $8.94 billion in profits. Earnings per share was $3.58.
| Revenue | 65.77B |
| Gross Profit | 50.46B |
| Operating Income | 24.53B |
| Pretax Income | 11.63B |
| Net Income | 8.94B |
| EBITDA | 18.21B |
| EBIT | 11.96B |
| Earnings Per Share (EPS) | $3.58 |
Balance Sheet
The company has $5.70 billion in cash and $49.12 billion in debt, with a net cash position of -$43.42 billion or -$17.58 per share.
| Cash & Cash Equivalents | 5.70B |
| Total Debt | 49.12B |
| Net Cash | -43.42B |
| Net Cash Per Share | -$17.58 |
| Equity (Book Value) | 45.93B |
| Book Value Per Share | 18.58 |
| Working Capital | 8.07B |
Cash Flow
In the last 12 months, operating cash flow was $17.89 billion and capital expenditures -$3.78 billion, giving a free cash flow of $14.12 billion.
| Operating Cash Flow | 17.89B |
| Capital Expenditures | -3.78B |
| Depreciation & Amortization | 4.98B |
| Net Borrowing | 13.80B |
| Free Cash Flow | 14.12B |
| FCF Per Share | $5.71 |
Margins
Gross margin is 76.73%, with operating and profit margins of 37.30% and 13.59%.
| Gross Margin | 76.73% |
| Operating Margin | 37.30% |
| Pretax Margin | 17.68% |
| Profit Margin | 13.59% |
| EBITDA Margin | 27.68% |
| EBIT Margin | 18.18% |
| FCF Margin | 21.46% |
Dividends & Yields
This stock pays an annual dividend of $3.40, which amounts to a dividend yield of 2.61%.
| Dividend Per Share | $3.40 |
| Dividend Yield | 2.61% |
| Dividend Growth (YoY) | 4.94% |
| Years of Dividend Growth | 15 |
| Payout Ratio | 95.08% |
| Buyback Yield | 1.79% |
| Shareholder Yield | 4.40% |
| Earnings Yield | 2.78% |
| FCF Yield | 4.39% |
Analyst Forecast
The average price target for Merck & Co. is $135.19, which is 3.83% higher than the current price. The consensus rating is "Buy".
| Price Target | $135.19 |
| Price Target Difference | 3.83% |
| Analyst Consensus | Buy |
| Analyst Count | 28 |
| Revenue Growth Forecast (3Y) | 4.59% |
| EPS Growth Forecast (3Y) | 5.81% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | |
| Lynch Upside | |
| Graham Number | |
| Graham Upside |
Stock Splits
The last stock split was on February 17, 1999. It was a forward split with a ratio of 2:1.
| Last Split Date | Feb 17, 1999 |
| Split Type | Forward |
| Split Ratio | 2:1 |
Scores
Merck & Co. has an Altman Z-Score of 3.62 and a Piotroski F-Score of 4.
| Altman Z-Score | 3.62 |
| Piotroski F-Score | 4 |